Retatrutide, a groundbreaking dual-acting glucose-responsive incretin agent, represents a significant progression in peptide medicines for the management of type 2 diabetes and, increasingly, weight issues. Unlike many existing read more therapeutic interventions, retatrutide combines the actions of a GLP-1 receptor agonist and a GIP receptor agoni